Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

291
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
291
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

84
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
84
Tumor Progression02:07

Tumor Progression

6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
Actuarial Approach01:20

Actuarial Approach

39
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
39
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

52
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
52

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

BPI26-018: Integrated Specialty Prostate Cancer Care: Outcomes From a Collaborative Clinic Model at UC San Diego Moores Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

European Association of Urology Guidelines on Testicular Cancer: Summary of the 2026 Guidelines.

European urology·2026
Same author

Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort study.

EClinicalMedicine·2026
Same author

BPI26-018: Integrated Specialty Prostate Cancer Care: Outcomes From a Collaborative Clinic Model at UC San Diego Moores Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Molecular Characterization of KLK2 RNA Expression in Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: May 9, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K

Key Updates in Testicular Cancer: Optimizing Survivorship and Survival.

Aditya Bagrodia1,2, Hege Sagstuen Haugnes3,4, Ragnhild Hellesnes3,4

  • 1Department of Urology and Radiation Medicine, UC San Diego School of Medicine, La Jolla, CA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 5, 2025
PubMed
Summary

Testicular cancer survivors face long-term health risks like endocrine dysfunction and cardiovascular disease despite high cure rates. This review highlights managing these survivorship issues with a multidisciplinary approach for better quality of life.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.1K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K

Related Experiment Videos

Last Updated: May 9, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.1K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K

Area of Science:

  • Oncology
  • Survivorship Research
  • Internal Medicine

Background:

  • Testicular cancer is a rare malignancy with high cure rates, primarily affecting young men.
  • Advances in multimodal therapy have improved survival but introduced long-term health concerns for survivors.
  • Survivorship issues, including endocrine dysfunction, cardiovascular disease, and secondary malignancies, are critical concerns.

Purpose of the Study:

  • To review the evolving landscape of testicular cancer survivorship.
  • To discuss the impact of treatment-related complications on survivors.
  • To outline contemporary management strategies for optimizing long-term outcomes and quality of life.

Main Methods:

  • Literature review of testicular cancer survivorship.
  • Analysis of treatment-related complications and their long-term effects.
  • Discussion of contemporary multidisciplinary management strategies.

Main Results:

  • Testicular cancer survivors are at increased risk for endocrine dysfunction (hypogonadism, infertility), cardiovascular disease, secondary malignancies, neuropathy, and psychosocial challenges.
  • Therapeutic de-escalation strategies are being developed for specific stages to minimize toxicity.
  • A multidisciplinary approach is essential for managing these complex survivorship issues.

Conclusions:

  • Optimizing long-term outcomes and quality of life for testicular cancer survivors requires proactive monitoring and management of treatment-related complications.
  • Continued research into de-escalation of therapy and comprehensive survivorship care is crucial.
  • A multidisciplinary team approach is fundamental to addressing the diverse health needs of testicular cancer survivors.